Future Aranesp Discounts Would Respond To Procrit Price Changes, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
First quarter Aranesp pricing adjustments were Amgen’s answer to J&J’s new Procrit clinic contracts. Since the February price changes, Aranesp market share has grown five points, Amgen says.